BSE filing, NSE: SPARC. Summary written from the filing by ALFA Finder's alert engine.
Sun Pharma Advanced Research Company Ltd: key numbers
- Share price
- ₹182.31
- Market cap
- ₹5,916 Cr
- Revenue (annual)
- ₹1,879 Cr
- Net profit (annual)
- ₹1,553 Cr
- P/E (TTM)
- 3.7×Sector 46.5×
- Promoter holding
- 65.67%+0.00% QoQ
- FII holding
- 3.74%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sun Pharma Advanced Research Company Ltd
All →Sun Pharma Advanced Research Company Board Meeting Date
SPARC intimated its Board will meet November 2, 2026 to consider Q1 and H1 FY27 unaudited results. Insider trading window stays closed until 48 hours post-declaration.
Sun Pharma Advanced Research Company Other Announcement
Sun Pharma Advanced Research Company Ltd has filed its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Sun Pharma Advanced Research Company Legal & Regulatory
The company secured a favorable CESTAT order confirming its entitlement to a Rs. 27.51 Crore CENVAT credit refund. This concludes the litigation in the company's favor.
- Value
- ₹27.51 Cr
Sun Pharma Advanced Research Company Promoter Reclassification
Sun Pharma Advanced Research Company has submitted an application to stock exchanges to reclassify certain members from 'Promoter Group' to 'Public' category.
Sun Pharma Advanced Research Company Annual General Meeting
SPARC held its 21st Annual General Meeting on August 10, 2026, via video conferencing. The meeting covered routine business, including adoption of financial statements.
Sun Pharma Advanced Research Company Other Announcement
Sun Pharma Advanced Research Company Limited submitted the Monitoring Agency Report for the quarter ended June 30, 2026. The report confirms zero deviation in utilizing proceeds from its Rs. 599.98 Crore warrant issue.
- Value
- ₹600.0 Cr
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.